
Computational Drug Development Strategies to Target HIV-1
A New Applications in Drug Discovery
Versandkostenfrei!
Versandfertig in 6-10 Tagen
51,99 €
inkl. MwSt.
PAYBACK Punkte
26 °P sammeln!
In the battle between human antiretroviral drug therapy techniques and HIV-1 microevolution, HIV-1 is currently outpacing human antiretroviral drug therapy techniques: all treatments ultimately end in HIV-1 developing resistance to the treatment. Some scientists believe humans are pushing the microevolution of HIV-1 toward more resistant viruses. For example, some researchers claim that human drug therapies are accelerating retrovirus evolution through drug therapies that select for resistant viruses. Human intervention on HIV-1 evolution through drug therapies has also been accused of being d...
In the battle between human antiretroviral drug therapy techniques and HIV-1 microevolution, HIV-1 is currently outpacing human antiretroviral drug therapy techniques: all treatments ultimately end in HIV-1 developing resistance to the treatment. Some scientists believe humans are pushing the microevolution of HIV-1 toward more resistant viruses. For example, some researchers claim that human drug therapies are accelerating retrovirus evolution through drug therapies that select for resistant viruses. Human intervention on HIV-1 evolution through drug therapies has also been accused of being detrimental to the ultimate goal of finding a permanent cure for HIV-1.